BRG1

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Retrieved on: 
Montag, Mai 6, 2024
Chromatin, Protein, SMARCA4, BRG1, Security, Research, SMARCA2, IND, Prostate cancer, LDAC, Acetyltransferase, BRM, AACR, Lung cancer, Multiple myeloma, AML, CBP, ARID1B, Lilly, Complex, Merck, NSCLC, DLBCL, ARID1A, Survival, Thrombocytopenia, Therapy, Gene expression, Biology, Cancer, Prostate, Data, Patient, Selective, SWI/SNF, Neoplasm, MDS, Anemia, Pharmaceutical industry

In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.

Key Points: 
  • In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.
  • In April 2024, Foghorn hosted the first Future of Disease and Chromatin Regulation Summit at the Foghorn corporate headquarters in Cambridge, Massachusetts.
  • In April 2024, Foghorn appointed Kristian Humer as Chief Financial Officer.
  • In April, Foghorn presented new pharmacodynamic and pharmacokinetic preclinical data at the 2024 AACR Annual Meeting highlighting:
    No observed thrombocytopenia in vivo.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
Dienstag, April 9, 2024
Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Montag, Januar 8, 2024
LDAC, Medicine, IND, Colorectal cancer, EGFR, BRG1, Prostate cancer, Factorization of polynomials, MDS, Thrombocytopenia, Gene expression, Chromatin, Neoplasm, Prostate, CBP, Cancer, Patient, Safety, ARID1B, AML, NSCLC, BRM, EP300, Pharmaceutical industry

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
Donnerstag, November 2, 2023
Research, NSCLC, EP300, IND, Thrombocytopenia, MDS, Preclinical development, Colorectal cancer, Merck, Chromatin, Factorization of polynomials, Prostate cancer, Hanson, LDAC, ARID1B, Clinical trial, CBP, BRG1, BRM, Safety, Investment, AR, Patient, Gene expression, BAF, Prostate, Mutation, State Administrative Expenses, Cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn, AML

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on: 
Mittwoch, Oktober 4, 2023
Synovial sarcoma, AACR, UM, CBP, DLBCL, Foghorn, NGS, Chromatin, BRM, BRG1, Mum, Gene expression, NSCLC, Prostate, Biomarker, Lung cancer, EP300, Acute myeloid leukemia, B cell, MDS, Malignancy, AML, BAF, Patient, Lymphoma, Neoplasm, BRD9, AR, Conference, Prostate cancer, Pharmaceutical industry, Vaccine, Science

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points: 
  • The conference will be held October 11–15, 2023, in Boston, Massachusetts.
  • Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
  • Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Retrieved on: 
Freitag, August 4, 2023
ARID1B, Therapy, CBP, Selective, CDX, Chromatin, Clinical trial, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, EP300, Preclinical development, PDX, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, LDAC, Biology, Research, IND, Factorization of polynomials, Safety, Prostate cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn

CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2023. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “Foghorn made important progress across both our clinical and preclinical pipeline in the second quarter.
  • We are on track to initiate dosing in a combination study of FHD-286 in AML in the third quarter.
  • On June 28, 2023, Foghorn announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).
  • As of June 30, 2023, the Company had $284.3 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025.

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

Retrieved on: 
Montag, Mai 8, 2023
Synovial sarcoma, ARID1B, Therapy, CBP, Selective, Chromatin, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, Lung cancer, EP300, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, Data, Biology, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Conference, Factorization of polynomials, Food, Prostate cancer, Pharmaceutical industry, Cryptocurrency, Foghorn

Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.

Key Points: 
  • Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.
  • The Company anticipates providing a regulatory update for FHD-286 in AML/MDS in the second quarter of 2023.
  • On April 24, 2023, Foghorn provided an update on the FHD-609 Phase 1 program in synovial sarcoma and SMARCB1-deleted tumors.
  • In 2023, Foghorn will continue to utilize its Gene Traffic Control platform to discover and develop novel therapeutics under the collaboration based on disruptors of a specified transcription factor target.

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meetin

Retrieved on: 
Montag, April 10, 2023
AACR, Selective, CBP, Foghorn, Chromatin, Skin, BRM, Uveal melanoma, Breast, BRG1, Gene expression, NSCLC, Prostate, Lung cancer, EP300, Lung, MDS, Malignancy, AML, Discovery, BAF, Lymphoma, Leukemia, Therapy, MD Anderson Cancer Center, Biology, Pharmaceutical industry, Glass fiber, Management, Science

Also at AACR, the company will provide an overview of its Selective EP300 and Selective CBP degrader programs.

Key Points: 
  • Also at AACR, the company will provide an overview of its Selective EP300 and Selective CBP degrader programs.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.
  • The CBP program is focused on a wide number of EP300 mutant cancers, including prostate, bladder, colorectal, breast, gastric, and lung.
  • If successful, the Selective EP300 and Selective CBP programs have the potential to address significant unmet medical need in large patient populations.

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

Retrieved on: 
Donnerstag, März 9, 2023
Fred Hutchinson Cancer Research Center, Survival, Mutation, Merck, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Malignancy, Prostate cancer, Food, Senior, ARID1A, Drug discovery, Therapy, Breast, BAF, EP300, Selective, IND, Acute leukemia, Myelodysplastic syndrome, Chromatin, Lung cancer, BRM, CREB, Mum, Gene expression, Lymphoma, CBP, Investment, Development, ARID1B, Ionis Pharmaceuticals, Synovial sarcoma, BRG1, Cancer, NSCLC, AML, Trial of the century, MDS, Uveal melanoma, Collaboration, Patient, State Administrative Expenses, Lilly, BRD9, Lung, Leukemia, Factorization of polynomials, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, Foghorn

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “2022 was a productive year for Foghorn as we made significant progress advancing our robust preclinical and clinical pipeline,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In 2023, Foghorn will continue to leverage its Gene Traffic Control platform to discover and develop novel therapeutics based on disruptors of an undisclosed transcription factor target.
  • In 2022, Foghorn announced Steven Bellon, Ph.D., former Senior Vice President of Drug Discovery, was promoted to Chief Scientific Officer.
  • During 2022, Foghorn announced the election of B. Lynne Parshall, Esq., and Thomas J. Lynch Jr., M.D., to its Board of Directors.

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

Retrieved on: 
Montag, Dezember 5, 2022
Foghorn, BRG1, Cell, ClinicalTrials.gov, Protein, Leukemia, SMARCA4, ATPase, Security (finance), MDS, Poster, Cancer, Bone marrow, Choroid, Gene expression, Acute leukemia, ASH, Pharmacology, BAF, BRM, Iris, AML, Ciliary body, SMARCA2, Acute myeloid leukemia, Drug resistance, Research, Society, Chromatin, Therapy, Blood, Patient, MD Anderson Cancer Center, Pharmaceutical industry, Dietary supplement, Science

Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Key Points: 
  • Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
    The poster will be accessible following the presentation under the Science section of the Company’s website.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.